Milind Deshpande

Health Innovations (United States) — United States

Medicine · Health Sciences

29h-index2.7kcitations89works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(20), Hepatitis C virus research(17), Chemical Synthesis and Analysis(11), Synthesis and biological activity(10), Cancer therapeutics and mechanisms(10)

Publications89 total

Āyurpadaviśleṣikā: A Digital Knowledge System for Ayurvedic Lexicography and Pharmacology
SSRN Electronic Journal·2025Open Access
A survey of core replacements in indole-based HIV-1 attachment inhibitors
Bioorganic & Medicinal Chemistry Letters·2019· 24 cited
Ferrocene-based inhibitors of hepatitis C virus replication that target NS5A with low picomolar in vitro antiviral activity
Bioorganic & Medicinal Chemistry Letters·2018· 12 cited
Preclinical Evaluation of Orally Bioavailable Small-Molecule Inhibitors of Complement Factor D As a Potential Treatment for Paroxysmal Nocturnal Hemoglobinuria
Blood·2014· 6 cited
Novel Small-Molecule Inhibitors Targeting Complement Factor D for Therapy of Paroxysmal Nocturnal Hemoglobinuria
Blood·2014· 8 cited
ACH-806, an NS4A Antagonist, Inhibits Hepatitis C Virus Replication by Altering the Composition of Viral Replication Complexes
Antimicrobial Agents and Chemotherapy·2013· 11 citedOpen Access
876 ACH-3102, A SECOND GENERATION NS5A INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY IN PATIENTS WITH GENOTYPE 1a HCV INFECTION DESPITE THE PRESENCE OF BASELINE NS5A-RESISTANT VARIANTS
Journal of Hepatology·2013· 10 cited
1201 NO CLINICALLY SIGNIFICANT PHARMACOKINETIC INTERACTION BETWEEN SOVAPREVIR AND ACH-3102 IN HEALTHY VOLUNTEERS
Journal of Hepatology·2013· 1 citedOpen Access
847 ACH-2684 DEMONSTRATES POTENT VIRAL SUPPRESSION IN GENOTYPE 1 HEPATITIS C PATIENTS WITH AND WITHOUT CIRRHOSIS: SAFETY, PHARMACOKINETIC, AND VIRAL KINETIC ANALYSIS
Journal of Hepatology·2013· 5 citedOpen Access
1200 FINDINGS FROM CLINICAL VIROLOGY STUDIES ON SOVAPREVIR, A PHASE 2 HCV NS3 PROTEASE INHIBITOR, INDICATE A HIGH PHARMACOLOGICAL BARRIER TO VIRAL RESISTANCE
Journal of Hepatology·2013Open Access
1199 FINDINGS FROM CLINICAL VIROLOGY STUDIES ON ACH-3102 ARE CONSISTENT WITH PRECLINICAL OBSERVATIONS ON ITS IMPROVED POTENCY AGAINST GENOTYPE-1a HCV AND RESISTANT VARIANTS
Journal of Hepatology·2013· 2 cited
Rapid and Sharp Decline in HCV upon Monotherapy with Ns3 Protease Inhibitor, Ach-1625
Antiviral Therapy·2012· 15 cited
845 PRECLINICAL CHARACTERISTICS OF ACH-3102: A NOVEL HCV NS5A INHIBITOR WITH IMPROVED POTENCY AGAINST GENOTYPE-1A VIRUS AND VARIANTS RESISTANT TO 1ST GENERATION OF NS5A INHIBITORS
Journal of Hepatology·2012· 18 cited
1182 CHARACTERIZATION OF HCV NS3 PROTEASE VARIANTS FROM PATIENTS ENROLLED IN A 28-DAY PHASE 2A TRIAL OF ACH-1625 DAILY DOSING PLUS PEGIFN-ALPHA 2A/RBV
Journal of Hepatology·2012· 7 cited
Discovery of a Novel Class of Bicyclo[3.1.0]hexanylpiperazines as Noncompetitive Neuropeptide Y Y1 Antagonists
ACS Medicinal Chemistry Letters·2012· 2 citedOpen Access
In Vitro and In Vivo Profiles of ACH-702, an Isothiazoloquinolone, against Bacterial Pathogens
Antimicrobial Agents and Chemotherapy·2011· 54 citedOpen Access
Selenophene-Containing Inhibitors of Type IIA Bacterial Topoisomerases
Journal of Medicinal Chemistry·2011· 55 citedOpen Access
Exploration of the Activity of 7-Pyrrolidino-8-methoxyisothiazoloquinolones against Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA)
Journal of Medicinal Chemistry·2011· 33 citedOpen Access
458 FINAL RESULTS OF THE PHARMACOKINETICS, EFFICACY, AND SAFETY/TOLERABILITY OF 400 AND 600 MG ONCE-DAILY DOSING OF ACH-1625 (HCV NS3 PROTEASE INHIBITOR) IN HCV GENOTYPE 1
Journal of Hepatology·2011· 5 citedOpen Access
1212 ACH-2928: A NOVEL HIGHLY POTENT HCV NS5A INHIBITOR WITH FAVORABLE PRECLINICAL CHARACTERISTICS
Journal of Hepatology·2011· 9 cited
page 1 of 5Next →

Frequent Co-authors

Barton J. Bradbury(11), Jason A. Wiles(10), Michael J. Pucci(10), Jane A. Thanassi(10), Nicholas A. Meanwell(9), Avinash Phadke(7), Steven D. Podos(7), Jijun Cheng(7), Owen B. Wallace(6), Qiuping Wang(6), Akihiro Hashimoto(6), Christy L. Thoma(6), Atul Agarwal(6), Edlaine Lucien(5), Christopher W. Marlor(5), Mingjun Huang(5), Yi-Fei Gong(4), Wade Blair(4), Pei‐Yong Shi(4), Richard J. Colonno(4)